Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 31 Issue 4, April 2013

Editorial

  • Genetically defined germ-free animal models colonized with defined microbiota are crucial for progress in microbiome research.

    Editorial

    Advertisement

  • The brand biotech industry is erecting barriers to biosimilars that will slow market entry and torpedo price competition.

    Editorial
Top of page ⤴

News

Top of page ⤴

Data Page

Top of page ⤴

News Feature

  • Burgeoning research on the human microbiome is facilitating the development of more mechanistically driven probiotics. Charles Schmidt investigates a smattering of probiotic- and microbiota-modifying therapeutic opportunities arising from commercial efforts.

    • Charles Schmidt
    News Feature
  • A survey of leading scientists from academia and industry highlights notable papers that have garnered momentum in microbiome research.

    • Susan Jones
    News Feature
Top of page ⤴

Bioentrepreneur

  • With acquisition the most likely exit for today's biotech investors, it pays to keep current with the tastes of pharmaceutical firms when launching a venture.

    • Asiya Giniatullina
    • Marco Boorsma
    • Sander van Deventer
    Bioentrepreneur
Top of page ⤴

Correspondence

Top of page ⤴

Commentary

  • Open collaboration on biomedical discoveries requires a fundamental shift in the traditional roles and rewards for both investigators and participants in research.

    • Stephen H Friend
    • Thea C Norman
    Commentary
Top of page ⤴

Feature

  • Nine experts discuss the challenges in translating current research on the human microbiome into strategies for disease prediction, diagnosis and therapy.

    • James Brown
    • Willem M de Vos
    • Peter Turnbaugh
    Feature
  • Five years after the launch of the Human Microbiome Project, several ventures are seeking to capitalize on the clinical promise of microbiome modulation. Commercialization of drugs that influence the human flora poses some unique scientific, translational and regulatory challenges.

    • Bernat Olle
    Feature
Top of page ⤴

Patents

Top of page ⤴

News & Views

  • siRNAs for knocking down target genes in mammalian cells can now be made in bacteria.

    • James A Blau
    • Michael T McManus
    News & Views
  • The entire metabolic pathway for producing a biofuel is confined within a yeast organelle to increase yield over the endogenous pathway split between two compartments.

    • William C DeLoache
    • John E Dueber
    News & Views
Top of page ⤴

Analysis

Top of page ⤴

Brief Communication

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Careers and Recruitment

Top of page ⤴

In This Issue

Top of page ⤴

Focus

  • Researchers have generated more than 3.5 terabytes of human microbiome genomic information – more than 1,000 times that generated by the Human Genome Project. This Focus highlights progress in microbiome research and how these data might translate into a better understanding of human diseases and rational design of new therapies.

    Focus
Top of page ⤴

Search

Quick links